Non Muscle Invasive Bladder Cancer Pipeline Insight

DelveInsight’s, “Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Non Muscle Invasive Bladder Cancer Understanding

Non Muscle Invasive Bladder Cancer: Overview

Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.


"Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non Muscle Invasive Bladder Cancer pipeline landscape is provided which includes the disease overview and Non Muscle Invasive Bladder Cancer treatment guidelines. The assessment part of the report embraces, in depth Non Muscle Invasive Bladder Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.

Non Muscle Invasive Bladder Cancer Emerging Drugs Chapters

This segment of the Non Muscle Invasive Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Non Muscle Invasive Bladder Cancer Emerging Drugs


UGN-102: UroGen Pharma

UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Non Muscle Invasive Bladder Cancer.


Sasanlimab: Pfizer

Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells. PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. Pfizer is developing PF-06801591 for the treatment of Non-muscle Invasive Bladder Cancer and is currently in phase III stage of development.

Further product details are provided in the report……..

Non Muscle Invasive Bladder Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Non Muscle Invasive Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Non Muscle Invasive Bladder Cancer

There are approx. 30+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, UroGen Pharma.

Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non Muscle Invasive Bladder Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Non Muscle Invasive Bladder Cancer therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non Muscle Invasive Bladder Cancer drugs.

Non Muscle Invasive Bladder Cancer Report Insights

  • Non Muscle Invasive Bladder Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Non Muscle Invasive Bladder Cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Non Muscle Invasive Bladder Cancer drugs?
  • How many Non Muscle Invasive Bladder Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non Muscle Invasive Bladder Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non Muscle Invasive Bladder Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Non Muscle Invasive Bladder Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Non Muscle Invasive Bladder Cancer: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Non Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

UGN-102: UroGen Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

TLD 1433: Theralase Technologies

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

VAX-014: Vaxiion Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

  • Comparative Analysis

Vesibax: Prokarium

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Non Muscle Invasive Bladder Cancer Key Companies

Non Muscle Invasive Bladder Cancer Key Products

Non Muscle Invasive Bladder Cancer- Unmet Needs

Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers

Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion

Non Muscle Invasive Bladder Cancer Analyst Views

Appendix

List of Table

Table 1: Total Products for Non Muscle Invasive Bladder Cancer

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Non Muscle Invasive Bladder Cancer

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products   

• UroGen Pharma

• CG Oncolgy

• Sasanlimab

• Sesen Bio

• Theralase Technologies

• Asieris Pharmaceuticals

• Hamlet Pharma

• AstraZeneca

• Viralytics

• ImmunityBio

• Prokarium

• Vaxiion Therapeutics

• Janssen Pharmaceuticals

• Abraxis Bioscience

• LIPAC Oncology

• Rapamycin Holdings

• Incyte Corporation

• Taizhou Hanzhong biomedical

  • Tags:
  • Non Muscle Invasive Bladder Cancer...
  • Non Muscle Invasive Bladder Cancer...
  • Non Muscle Invasive Bladder Cancer...
  • Non Muscle Invasive Bladder Cancer...
  • Non Muscle Invasive Bladder Cancer...
  • Non Muscle Invasive Bladder Cancer...
  • Non Muscle Invasive Bladder Cancer...
  • Non Muscle Invasive Bladder Cancer...

Forward to Friend

Need A Quote